As a clinical-stage biotechnology enterprise focused heavily on intensive research, drug discovery, and multi-country clinical trials, Apogee Therapeutics has historically operated at a financial loss. The company does not generate commercial product sales revenue yet, recording periodic net operational losses while funding its pipeline developments through public offerings and strategic financing collaborations.